ONO Pharma

Autoimmune and inflammatory diseases affect millions worldwide, driving demand for more targeted and effective therapies.

Ono Pharmaceutical Co., Ltd. has signed two licence agreements with Monash University to develop and commercialise anti-GPCR antibody therapies, following a three-year research collaboration led by Associate Professor Remy Robert. These antibodies target G-protein-coupled receptors, a major class of drug targets across many disease areas. The agreements position Monash and Ono to accelerate new treatment options for patients with significant unmet medical needs.

Lead Researcher: Associate Professor Remy Robert

Website: https://www.ono-pharma.com/en